Department of Pharmacy, National University of Singapore, Singapore 117543, Singapore.
Int J Pharm. 2013 Jun 25;450(1-2):114-22. doi: 10.1016/j.ijpharm.2013.04.011. Epub 2013 Apr 20.
Pulmonary hypertension (PAH) is a condition of the lungs characterised by an elevated arterial pressure and increased vascular resistance. Existing medications have to be administered frequently, resulting in non compliance by patients. Little work has been reported to date where microspheres have been developed to control the release of drug for treatment of pulmonary hypertension. To transcend this drawback, controlled release microspheres were formulated to minimise the number of doses required for treatment of PAH. Nifedipine and polyvinyl alcohol (PVA) were used as the model drug and release modifier respectively. Microspheres were developed by varying the PVA concentration using the spray drying technique. The formulated microspheres were characterised in terms of particle size, morphology, crystallinity, interaction between PVA and nifedipine via Fourier transformed infra-red spectroscopy (FTIR) and differential scanning calorimetry (DSC), in vitro release profile by employing the United States Pharmacopeia Apparatus type II and in vitro aerosolisation profile by using multi-stage liquid impinger (MSLI). The toxicity of PVA on lung epithelial cells was tested using human alveolar basal epithelium A549 cell line. From the data, it was observed that the microspheres were within the inhalable range (1-10 μm) with spherical morphology. The X-ray diffraction demonstrated that the microspheres were amorphous. There was no interaction between PVA and nifedipine during the formation of microspheres as seen by FTIR. The in vitro release profile showed a burst release followed by controlled release. A more prolonged release can be achieved by increasing the PVA:nifedipine ratio. In vitro aerosolisation showed that the Fine Particle Fractionemitted of the microspheres is greater than 20%, which is similar to that of marketed inhalation formulations. PVA was found to have insignificant effect on cell viability after 48 h of exposure to A549 cell line. In conclusion, microspheres of nifedipine and PVA, prepared by spray drying were found to exhibit suitable properties to achieve controlled release by the inhalation route.
肺动脉高压(PAH)是一种肺部疾病,其特征是动脉压升高和血管阻力增加。现有的药物需要频繁给药,导致患者不遵守医嘱。迄今为止,很少有报道开发微球来控制药物释放以治疗肺动脉高压。为了克服这一缺点,开发了控释微球以尽量减少治疗 PAH 所需的剂量数。硝苯地平和聚乙烯醇(PVA)分别用作模型药物和释放调节剂。通过喷雾干燥技术改变 PVA 浓度来开发微球。通过采用美国药典仪器 II 型体外释放曲线和多阶段液体撞击器(MSLI)体外雾化曲线,对微球的粒径、形态、结晶度、PVA 与硝苯地平之间的相互作用进行了表征,通过傅里叶变换红外光谱(FTIR)和差示扫描量热法(DSC)。在使用人肺泡基底上皮 A549 细胞系测试 PVA 对肺上皮细胞的毒性后。从数据中可以观察到,微球在可吸入范围内(1-10μm),具有球形形态。X 射线衍射表明微球为无定形。FTIR 表明在微球形成过程中 PVA 和硝苯地平之间没有相互作用。体外释放曲线显示出爆发释放,随后是控制释放。通过增加 PVA:硝苯地平的比例,可以实现更持久的释放。体外雾化表明微球的细颗粒分数大于 20%,与市售吸入制剂相似。在暴露于 A549 细胞系 48 小时后,发现 PVA 对细胞活力没有显著影响。总之,通过喷雾干燥制备的硝苯地平和 PVA 微球具有合适的性质,可以通过吸入途径实现控制释放。